GLUE.US Monte Rosa Therapeutics Inc

Healthcare Biotechnology USA Stocks
9.37 USD
Close of Nov 14, 2026
8.95 25.77
Market cap
USD 801M
P/E
-
P/B
1.60x
ROE
-22.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GLUE.US undervalued?

Graham number

The Graham number of Monte Rosa Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Monte Rosa Therapeutics Inc fundamental analysis

No fundamental analysis for Monte Rosa Therapeutics Inc yet.

Monte Rosa Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 f…

Full company profile